➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-8330

Email this page to a colleague

« Back to Dashboard

What is the drug development status for AZD-8330?

AZD-8330 is an investigational drug.

There have been 31 clinical trials for AZD-8330. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).

Recent Clinical Trials for AZD-8330
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsAstraZenecaPhase 2
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsSamsung Medical CenterPhase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2

See all AZD-8330 clinical trials

Clinical Trial Summary for AZD-8330

Top disease conditions for AZD-8330
Top clinical trial sponsors for AZD-8330

See all AZD-8330 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.